AbCellera Biologics Inc. has appointed Dr. Lynn Seely as a new Class III director to its Board of Directors, effective June 30, 2026. Dr. Seely is an independent director and will serve until the company's 2029 annual meeting of shareholders. She is recognized for her executive leadership and experience in developing new medicines across endocrinology, oncology, and women's health. Dr. Seely's background includes roles as CEO of Lyell Immunopharma Inc. and previously as CEO of Myovant Sciences Inc. She also served as Chief Medical Officer at Medivation Inc., overseeing the development of the oncology drug Xtandi. Dr. Seely's appointment is expected to leverage her expertise in strategic, clinical, and commercial execution for AbCellera's antibody-based medicine discovery and development.